NXGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, Nexgel Inc (NXGL) is not a strong buy at this moment. The stock lacks clear positive trading signals, has mixed financial performance, and faces potential downward pressure due to recent earnings misses. While the acquisition of Celularity's segment and the launch of BioNX Surgical are promising long-term catalysts, the immediate financial and technical outlook does not justify a buy recommendation.
The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 43.18, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level of 0.688, with support at 0.573 and resistance at 0.802, indicating limited upside in the short term.
The acquisition of Celularity's degenerative wound segment is expected to increase annual revenue to $35 million and improve profitability. The launch of the BioNX Surgical division could drive future commercial growth. Management anticipates positive EBITDA post-integration.
The company reported a significant earnings miss, with FY GAAP EPS of -$0.38 and revenue falling short of expectations by $5.46 million. This could lead to downward pressure on the stock. Additionally, the company's financials show declining revenue and continued net losses, raising concerns about its ability to sustain growth.
In Q4 2025, revenue dropped by 8.06% YoY to $2.796 million. Net income improved but remained negative at -$970,000. EPS remained flat at -$0.12, and gross margin increased to 29.29%, up 14.32% YoY. Despite some improvements, the overall financial performance remains weak.
Maxim lowered the price target from $6 to $2 while maintaining a Buy rating. The adjustment reflects dilution concerns from financing the Celularity acquisition. Analysts view the acquisition as potentially transformative but remain cautious about its immediate impact.
